Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT03193567
PHASE1
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
Sponsor: Ruijin Hospital
View on ClinicalTrials.gov
Summary
The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
Official title: Phase I Study of High Efficient Killing Cell Therapy for Advanced Non Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2017-09-14
Completion Date
2025-05-01
Last Updated
2024-11-19
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
HEKT cell
3 cycles of HEKT cell treatment
Locations (1)
Ruijin Hospital
Shanghai, China